Nerviano Medical Sciences S.r.l.

Merck Sharp + Dohme Corp.

Ron Ferguson

Maria Gabriella Brasca

Paolo Polucci

Paolo Pevarello

Daniele Fancelli

Achille Panzeri

Gabriella Traquandi

Paola Vianello

Anna Vulpetti

Francesca Quartieri

Roberto D'Alessio

Fulvia Roletto

Helena Posteri

Michele Caruso

Italo Beria

Francesco Casuscelli

Matteo D'Anello

Gianluca Mariano Enrico Papeo

Fabio Zuccotto

Giovanni Cervi

Elena Casale

Danilo Mirizzi

Joseph A Kozlowski

David James Witter

Xianhai Huang

Kevin J Wilson

David L Sloman

Phieng Siliphaivanh

Christopher W Boyce

Sergio Mantegani

Raman Kumar Bakshi

Umar Faruk Mansoor

Matthew H Daniels

Catherine M White

Wei Zhou

Salem Fevrier

Danielle Falcone

Shuyi Tang

Kathryn Ann Lipford

Brendan O'Boyle

Ravi Kurukulasuriya

Barbara Valsasina

Judson E Richard

Ganesh Babu Karunakaran

Angie R Angeles

Carlo Visco

Matteo D'anello

Roberto D'alessio

Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors

Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0). 

Compounds that are ERK inhibitors

The present invention relates to substituted resorcinol derivatives which inhibit the activity of Heat Shock Protein HSP90. The compounds of the invention are therefore useful in treating proliferative diseases such as cancer and neurodegenerative diseases. The present invention also provides processes for preparing these compounds, pharmaceutical compositions comprising them, methods of treating diseases and the pharmaceutical compositions comprising these compounds.

Resorcinol derivatives as HSP90 inhibitors

Compounds which are 4,7-disubstituted derivatives of 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one compounds, or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders; also disclosed is a process under Solid Phase Synthesis conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

Substituted 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-ones as modulators of protein kinase activity

Substituted pyrrolo-pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with dysregulated protein kinase activity, like cancer.

Substituted pyrrolo-pyrazole derivatives as kinase inhibitors

Pyrazolo-quinazoline derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer. 

Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors

Pyrazolo quinazoline derivatives, process for their preparation and their use as kinase inhibitors

Compounds which are 4,7-disubstituted derivatives of 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one compounds with the formula or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, viral infection, prevention of AIDS development in HIV-infected individuals, cell proliferative disorders, autoimmune and neurodegenerative disorders; also disclosed is a process under Solid Phase Synthesis conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives for the modulation of the activity of protein kinases

Bicyclic pyrazole and isoxazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases mediated by HSP90 protein, like cancer and neurodegenerative disorders.

Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents

Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

Growing community of inventors

Casale Litta, Italy

Ron Ferguson